
Sign up to save your podcasts
Or


Maureen Hillenmeyer is the Founder and CEO of Hexagon Bio, a cutting-edge biotech company whose mission is to harvest new drugs and cures from the natural world, beginning with fungi. In 1928, Sir Alexander Fleming’s accidental discovery of penicillin launched a new age of antibiotics derived from fungi. However, the process of discovery was slow and laborious. In this episode, Hillenmeyer explains how Hexagon is using genomic sequencing and artificial intelligence to analyze the millions of types of fungi on earth and uncover new drugs and cures for a host of diseases. She also issues an important warning about the looming crisis of antibiotic resistance and how Hexagon's work could avert a medical disaster. [Joe's venture capital firm is an investor in Hexagon Bio.]
By Joe Lonsdale4.5
155155 ratings
Maureen Hillenmeyer is the Founder and CEO of Hexagon Bio, a cutting-edge biotech company whose mission is to harvest new drugs and cures from the natural world, beginning with fungi. In 1928, Sir Alexander Fleming’s accidental discovery of penicillin launched a new age of antibiotics derived from fungi. However, the process of discovery was slow and laborious. In this episode, Hillenmeyer explains how Hexagon is using genomic sequencing and artificial intelligence to analyze the millions of types of fungi on earth and uncover new drugs and cures for a host of diseases. She also issues an important warning about the looming crisis of antibiotic resistance and how Hexagon's work could avert a medical disaster. [Joe's venture capital firm is an investor in Hexagon Bio.]

1,288 Listeners

537 Listeners

2,451 Listeners

1,085 Listeners

2,164 Listeners

2,004 Listeners

9,911 Listeners

505 Listeners

135 Listeners

141 Listeners

472 Listeners

121 Listeners

43 Listeners

3 Listeners

49 Listeners